Allergy Immunotherapy Market Size & Share

Global Market Size, Forecast, and Trend Highlights Over 2024- 2036

Allergy Immunotherapy Market size is poised to surpass USD 6 Billion by the end of 2036, growing at a CAGR of 10% during the forecast period, i.e., 2024 – 2036. In the year 2022, the industry size of allergic immunotherapy was over USD 2 Billion. Because more people are developing these allergies, the market is expanding. The healthcare system is challenged by complex allergies, which cause people's health to deteriorate too much. Asthma and other allergies that affect the body's respiratory system are on the rise as a result of the environment's increasing air pollution. As per a recent report, asthma was the primary diagnosis in 38,792 hospitalizations between 2017 and 2018. Also, Asthma-related fatalities totaled 417 in 2020.

Furthermore, a rising number of immunotherapy treatments are under development to treat patients' allergies. This element is anticipated to fuel market expansion. Sublingual immunotherapy has been investigated by certain researchers for a variety of food allergies, including those to milk, peanuts, kiwis, and peaches. Numerous studies have shown that therapy cannot be effective without consistent pharmaceutical use.

Allergic Immunotherapy Sector: Growth Drivers and Challenges

Growth Drivers

Growing Research and Development Activities - Increasing investments and financial support in the study of these allergies and the development of effective treatments for them. The market is expanding as a result of this. Immune Therapeutics is creating the biologic immunotherapy experimental medication AR101 for people with a peanut allergy.
Growing Prevalence of Allergies – An individual's quality of life is negatively impacted by allergic diseases because they disrupt many physiological processes. The demand for an efficient treatment method like allergy immunotherapy is growing due to the rising prevalence of allergies among people around the world as a result of increased exposure to numerous allergens such as pollens, mists, moulds, and others. For instance, in the US, about 25.7% of adults will have seasonal allergies by 2023, and about 31.8% of adults will have an allergy. This element is fueling market expansion.
Increasing Demand for Advanced Procedures – Pharma companies are able to expand their treatment options due to the rising prevalence of allergies and the ensuing medical therapies. Players are improving the already effective SLIT medications, which have been shown to treat atopic dermatitis, respiratory allergies, and a few food allergies. According to recent surveys, SLIT is still preferred by consumers over SCIT despite its drawbacks because of its accessibility. Additionally, a 10% annual increase in the prevalence of food allergies has been documented, which has increased the demand for immunotherapy for food allergies.

Challenges

Side Effects of Subcutaneous Injections – Patients do experience some alleviation from the subcutaneous injections, but there are some negative effects as well. The couple's adverse effects are anticipated to be hampered by these negative effects. During the projection period, these adverse consequences are anticipated to hurt the market.
Limitations Associated with Applicability of Allergy Immunotherapy
Poor Efficacy and Specificity of Immunotherapy

Allergy Immunotherapy Segmentation

Allergy Type (Allergic Rhinitis, Asthma, Allergic Conjunctivitis)

The rhinitis segment is expected to hold a significant share of the allergy immunotherapy market during the forecast period. According to a survey, rhinitis and asthma impact 23 million people in the US each year. In the same region, an additional 50 million people suffer from another type of allergy. One of the major drivers of the market expansion is the increased investment made by major manufacturers in the development of AIT medications to treat different allergies. Therefore, it is anticipated that allergic rhinitis will fuel the segment's expansion.

Treatment (Subcutaneous Immunotherapy, Sublingual Immunotherapy)

The subcutaneous immunotherapy segment would account for more than 53% of the allergy immunotherapy market. Subcutaneous immunotherapy (SCIT) is a cutting-edge method for treating allergic diseases because it alters allergic diseases by concentrating on the underlying immunological mechanism. Numerous carefully monitored clinical trials have demonstrated its efficacy and safety in the treatment of asthma, allergic rhinitis/rhino conjunctivitis, and hypersensitivity to stinging insects. Subcutaneous immunotherapy (SCIT), which is administered via injection, is frequently referred to as an "allergy shot". It provides symptomatic relief for those with asthma and allergic rhinitis and is the standard treatment for allergen desensitization. Increased prevalence of allergic disorders and high demand for improved procedures are some of the factors driving the growth of the segment. According to estimates, between 11 and 26 million people in Europe have food allergies. With a population of 7 billion people, this rate amounts to 240–550 million people who could be food allergies, which is a significant global health burden.

Our in-depth analysis of the global market includes the following segments:

Treatment	Subcutaneous Immunotherapy Sublingual Immunotherapy
Allergy Type	Allergic Rhinitis Asthma Allergic Conjunctivitis
Distribution Channels	Hospital Pharmacies Retail Pharmacies Online Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Allergy Immunotherapy Industry - Regional Synopsis

APAC Market Forecast

In the Asia Pacific allergy immunotherapy market is to generate the highest revenue by the end of 2036. Also, Asia Pacific is expected to hold a share of 36% during the forecast period. In countries, such as India and China, this is mainly due to the existence of a large proportion of the younger population that are more susceptible to sensitization. Moreover, a number of factors contributing to growth in this market in the Asia Pacific region are the presence of major key players in the market, investment from them, and uptake of medicines like Sublingual Immunotherapy with an overview of long-term results as well as dosage standardization.

North American Market Statistics

North America allergy immunotherapy market is expected to hold a significant share of 27% during the forecast period. The market expansion can be attributed to the region's high frequency of allergy diseases as well as the population's increased health consciousness. According to the World Allergy Organization, allergic rhinitis is the seventh most common chronic respiratory condition in the US, affecting 10–30% of the general adult population and approximately 405 children. A few other elements boosting the expansion in the area include high-end research and development, investments made by market participants, partnerships and acquisitions with significant industry participants, and strong emphasis on manufacturing facilities.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the allergic immunotherapy market?

Ans: Growing research and development activities and growing prevalence of allergies are some of the factors driving the market growth.

2) What would be the CAGR of the allergic immunotherapy market over the forecast period?

Ans: The market size of allergic immunotherapy is anticipated to attain a CAGR of 10% over the forecast period, i.e., 2024 â€“ 2036.

3) Who are the major players dominating the allergic immunotherapy market?

Ans: The major players in the market are ALK, Stallergenes Greer, Mylan N.V., HAL Allergy B.V., LETIPharma, AstraZeneca, Takeda Pharmaceuticals Company Ltd, Chugai Pharmaceutical Co., Ltd, Eisai Co. Ltd, Astellas Pharma Inc. and others.

4) Which segment captures the largest market size in the treatment segment in the allergic immunotherapy market?

Ans: The subcutaneous immunotherapy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

5) Which region will provide more business opportunities for the growth of the allergic immunotherapy market in the future?

Ans: The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Base Year	2023
Forecast Year	2024 - 2036
CAGR	~10%
Base Year Market Size (2023)	~USD 2 billion
Forecast Year Market Size (2036)	~USD 6 billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)